Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3526 |
|
| Actual shortage: | 229 (6%) | |
| Anticipated shortage: | 3 (0%) | |
| Avoided shortage: | 11 (0%) | |
| Resolved: | 3283 (93%) | |
Discontinuation Reports |
366 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 342 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
32 (13%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-CABERGOLINE | 0.5MG | TABLET | Resolved | 2018-02-26 | 2021-03-02 | 41136 |
| APO-CABERGOLINE | 0.5MG | TABLET | Resolved | 2023-12-15 | 2023-12-22 | 213587 |
| APO-CABERGOLINE | 0.5MG | TABLET | Resolved | 2024-01-12 | 2024-10-10 | 215982 |
| APO-CABERGOLINE | 0.5MG | TABLET | Resolved | 2025-06-05 | 2025-07-04 | 259729 |
| APO-CANDESARTAN | 16MG | TABLET | Resolved | 2017-03-11 | 2017-06-27 | 639 |
| APO-CANDESARTAN | 4MG | TABLET | Resolved | 2017-03-12 | 2018-09-09 | 706 |
| APO-CANDESARTAN | 32MG | TABLET | Resolved | 2017-03-20 | 2020-02-25 | 3516 |
| APO-CANDESARTAN | 4MG | TABLET | Resolved | 2017-08-08 | 2020-02-25 | 18517 |
| APO-CANDESARTAN | 8MG | TABLET | Resolved | 2017-08-08 | 2020-02-25 | 18520 |
| APO-CANDESARTAN | 16MG | TABLET | Resolved | 2018-01-03 | 2020-02-25 | 34838 |
| APO-CANDESARTAN | Resolved | 2020-03-09 | 2020-05-04 | 108228 | ||
| APO-CANDESARTAN | 8MG | TABLET | Resolved | 2020-04-13 | 2020-10-19 | 111895 |
| APO-CANDESARTAN | 32MG | TABLET | Resolved | 2020-05-13 | 2020-09-21 | 114928 |
| APO-CANDESARTAN | 16MG | TABLET | Resolved | 2020-06-24 | 2021-06-14 | 118761 |
| APO-CANDESARTAN | 16MG | TABLET | Resolved | 2020-06-24 | 2020-09-21 | 118763 |
| APO-CANDESARTAN | 4MG | TABLET | Resolved | 2020-10-21 | 2021-03-15 | 126768 |
| APO-CANDESARTAN | 16MG | TABLET | Resolved | 2021-05-14 | 2021-07-30 | 139406 |
| APO-CANDESARTAN | 32MG | TABLET | Actual shortage | 2021-10-22 | 2021-10-22 | 147815 |
| APO-CANDESARTAN | 32MG | TABLET | Actual shortage | 2022-03-11 | 2022-03-11 | 156534 |
| APO-CANDESARTAN | 4MG | TABLET | Actual shortage | 2022-08-12 | 2022-08-12 | 166589 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-FENTANYL MATRIX | 100MCG | PATCH | Discontinued | 2018-02-23 | 2018-12-28 | 40741 |
| APO-FENTANYL MATRIX | 25MCG | PATCH | Discontinued | 2018-09-07 | 2018-09-15 | 60489 |
| APO-FENTANYL MATRIX | Discontinued | 2018-09-07 | 2018-09-15 | 60494 | ||
| APO-FENTANYL MATRIX | 75MCG | PATCH | Discontinued | 2018-09-07 | 2018-09-15 | 60497 |
| APO-FLUNISOLIDE NASAL SPRAY | 0.25MG | METERED-DOSE PUMP | Discontinued | 2018-02-26 | 2018-02-26 | 40965 |
| APO-FLUVOXAMINE | 100MG | TABLET | Discontinued | 2017-03-30 | 2018-02-05 | 4713 |
| APO-FLUVOXAMINE | 50MG | TABLET | Discontinued | 2017-03-30 | 2018-02-05 | 4716 |
| APO-GAIN LIQ 20MG/ML | 20MG | SOLUTION | Discontinued | 2018-02-26 | 2018-02-26 | 40997 |
| APO-GAIN LIQ 20MG/ML | 20MG | SOLUTION | Discontinued | 2019-01-02 | 2019-01-02 | 70815 |
| APO-GEMFIBROZIL | 600MG | TABLET | Discontinued | 2017-03-31 | 2017-03-31 | 4927 |
| APO-GEMFIBROZIL CAP 300MG USP | 300MG | CAPSULE | Discontinued | 2017-03-31 | 2018-12-07 | 4920 |
| APO-GEMFIBROZIL CAP 300MG USP | Discontinued | 2019-06-12 | 2019-06-12 | 86557 | ||
| APO-GLICLAZIDE | 80MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60512 |
| APO-GLIMEPIRIDE | Discontinued | 2019-09-20 | 2019-09-20 | 94446 | ||
| APO-GLIMEPIRIDE | Discontinued | 2019-09-20 | 2019-09-20 | 94449 | ||
| APO-GLIMEPIRIDE | Discontinued | 2019-09-20 | 2019-09-20 | 94452 | ||
| APO-HALOPERIDOL TAB 2MG | 2MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1084 |
| APO-HALOPERIDOL TAB 5MG | 5MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1087 |
| APO-HYDROMORPHONE CR | 3MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110956 |
| APO-HYDROMORPHONE CR | 6MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110959 |